Form 4 for AXSM Axsome Therapeutics, Inc.
Accepted 2026-04-23 21:01:34 ET · period of report 2026-04-22 · accession 0001193125-26-174415 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-04-23 21:01 | 2026-04-22 | AXSM | Maizel Ari | Chief Commercial Off | M - OptEx | $70.73 | +7,500 | 7,500 | New | +$530.5K |
| DT | 2026-04-23 21:01 | 2026-04-22 | AXSM | Maizel Ari | Chief Commercial Off | S - Sale+OE | $182.42 | -7,500 | 0 | -100% | -$1.37M |
| DT | 2026-04-23 21:01 | 2026-04-22 | AXSM | Maizel Ari | Chief Commercial Off | M - OptEx | $0.00 | -7,500 | 23.7K | -24% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-04-22 | M | A | 7,500 | $70.73 | 7,500 | D | — | — | (F1) Such transaction was pursuant to a pre-approved 10b5-1 plan. |
| 2 | Common | Common Stock | 2026-04-22 | S | D | 7,500 | $182.42 | 0 | D | — | — | (F1) Such transaction was pursuant to a pre-approved 10b5-1 plan. (F2) Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options. (F3) Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $181.01 and $184.28. |
| 3 | Derivative | Stock Option (Right to Buy) | 2026-04-22 | M | D | 7,500 | $0.00 | 23,710 | D | $70.73 · 2024-09-25 to 2033-09-25 | 7,500 Common Stock | (F1) Such transaction was pursuant to a pre-approved 10b5-1 plan. |